Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | HRH2 | P25021 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | DHFR | P00374 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18123545 | 0.77 | KCNH2 (0.39) | KCNH2HRH4HRH3HRH2HRH1 | |
| SCHEMBL24506812 | 0.76 | DHFR (0.45) | KCNH2HRH4HRH3DHFRNPC1 | |
| SCHEMBL19520168 | 0.75 | KCNH2 (0.58) | KCNH2HRH4HRH3HRH2HRH1 | |
| SCHEMBL24506591 | 0.74 | KDM4E (0.38) | HRH4HRH3DHFRNPC1RAB9A | |
| SCHEMBL4572162 | 0.73 | LCK (0.49) | KCNH2HRH4HRH3DHFRNPC1 | |
| SCHEMBL2056395 | 0.73 | — | — | |
| SCHEMBL31347400 | 0.70 | ALDH1A1 (0.38) | KCNH2HRH4HRH3HRH2HRH1 | |
| SCHEMBL31347405 | 0.70 | ALDH1A1 (0.38) | KCNH2HRH4HRH3HRH2HRH1 | |
| SCHEMBL30112896 | 0.70 | CLK1 (0.43) | HRH4 | |
| SCHEMBL10077307 | 0.69 | EGFR (0.33) | KCNH2HRH4HRH3HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
| US-20220185792-A1 | PRMT5 INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185792-A1 | PRMT5 INHIBITOR COMPOUNDS | PRMT5, PRMT1, PRMT6 | KCNH2 3898/4885HRH4 942/4885HRH3 855/4885 |
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | PRMT5, PRMT1, PRMT6 | KCNH2 3898/4885HRH4 942/4885HRH3 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.